Abstract
Objective To evaluate the clinical value of 18F-FDG PET/CT in preoperative assessment for endometrial cancer. Methods A retrospective study was performed in 51 patients (average age (59±12) years) with confirmed or suspicious diagnosis of endometrial cancer from February 2013 to December 2015. Thirty-three patients underwent curettage surgery at least 1 week before PET/CT imaging. With SUVmax as the statistical variable, comparison was made between the pathologically confirmed benign and malignant groups, and in case of the latter, the extent of infiltration, histologic grade and subtype of primary tumor, lymph node and distant metastases were also analyzed. Two-sample t test was used to analyze the data, and diagnostic efficacy of PET/CT for metastasis was calculated. Results There were 43 patients with endometrial cancer and 8 patients with benign uterine tumor. SUVmax was found to significantly correlate with histopathology classification (benign: 3.4±1.2, malignant: 12.8±6.5) and depth of myometrial invasion (≥1/2: 17.7±5.4, 0.05). The sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of PET/CT for the detection of lymph node metastases on a lesion basis were 85.7%(18/21), 98.2%(271/276), 97.3%(289/297), 78.3%(18/23), 98.9%(271/274), respectively, and on a patient basis were 6/6, 97.3%(36/37), 97.7%(42/43), 6/7, 100%(36/36), respectively. The sensitivity and PPV of PET/CT for the detection of other metastases on a lesion basis were both 11/12. Conclusion SUVmax could be a clinically valuable tool for preoperative evaluation of the presence of deep myometrial invasion, lymph node metastases and other metastases in patients with endometrial cancer, particularly in specificity and NPV. Key words: Endometrial neoplasms; Neoplasm metastasis; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Nuclear Medicine and Molecular Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
